|
KMID : 1102220160350030142
|
|
Kidney Research and Clinical Practice
2016 Volume.35 No. 3 p.142 ~ p.146
|
|
|
Cicletanine-induced hyponatremia and hypokalemia in kidney transplant patients
|
|
Choi Eun-Young
Ro Young-Ouk
Choi Jong-Wook
Kang Chong-Myung
Kim Gheun-Ho
|
|
|
Abstract
|
|
|
Background: Cicletanine is an antihypertensive agent with vasorelaxant and diuretic properties. It has been widely used in European countries; however, cicletanine-associated electrolyte disturbances have yet to be defined. We investigated cicletanine-induced hyponatremia and hypokalemia in kidney transplant patients.
Methods: Data from a total of 68 kidney transplant recipients who were treated for hypertension with cicletanine were retrospectively analyzed. Cicletanine-induced hyponatremia and hypokalemia were defined as serum sodium
Results: The average patient age was 50 (±11)?years, and 44 (65%) were male. The daily dose of cicletanine was 171?±?46?mg, and the duration of drug use was 215?±?514?days. Hyponatremia occurred in 11 patients (16.2%), and hypokalemia occurred in 8 patients (11.8%). Three patients (4.4%) had hyponatremia and hypokalemia simultaneously. The duration of cicletanine administration was significantly longer in patients with hyponatremia than in those without hyponatremia (943?±?958 vs. 74?±?166?days, P?
Conclusion: We demonstrate that cicletanine may induce hyponatremia or hypokalemia in kidney transplant patients. Hyponatremia is more frequently associated with cicletanine than hypokalemia, and extended use of cicletanine may increase the risk of hyponatremia.
|
|
|
KEYWORD
|
|
|
Cicletanine, Hypokalemia, Hyponatremia, Kidney transplantation
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
   
|